About OSE Immunotherapeutics
OSE Immunotherapeutics is a company based in Nantes (France) founded in 1986. The company has 64 employees as of December 31, 2024. OSE Immunotherapeutics offers products and services including Tedopi, OSE-279, Lusvertikimab, and Pegrizeprument. OSE Immunotherapeutics operates in a competitive market with competitors including Biogen, CareDx, ADMA Biologics, Kymeratx and BioNTech, among others.
- Headquarter Nantes, France
- Employees 64 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ose Immunotherapeutics Sa
-
Annual Revenue
$72.6 M (USD)3037.72as on Dec 31, 2024
-
Net Profit
$38.91 M (USD)0as on Dec 31, 2024
-
EBITDA
$29.46 M (USD)0as on Dec 31, 2024
-
Latest Funding Round
$9.12 M (USD), Grant
Apr 10, 2024
- Investors
-
Employee Count
64
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OSE Immunotherapeutics
OSE Immunotherapeutics is a publicly listed company on the EURONEXT with ticker symbol OSE in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OSE Immunotherapeutics
OSE Immunotherapeutics offers a comprehensive portfolio of products and services, including Tedopi, OSE-279, Lusvertikimab, and Pegrizeprument.
Immunotherapy for activating T cells in cancer treatment.
Targets tumor microenvironment for oncology applications.
Regulates immune responses in inflammation disorders.
Modulates T cell activity for therapeutic use.
Funding Insights of OSE Immunotherapeutics
Investors in OSE Immunotherapeutics
OSE Immunotherapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate consultancy, advisory, and funding services are provided to businesses.
|
Locked | Locked | Locked |
Investor details for OSE Immunotherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OSE Immunotherapeutics
Investment portfolio details for OSE Immunotherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OSE Immunotherapeutics
Detailed financials for OSE Immunotherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ose Immunotherapeutics Comparisons
Peer comparison for OSE Immunotherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OSE Immunotherapeutics
OSE Immunotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, CareDx, ADMA Biologics, Kymeratx and BioNTech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Medical solutions for transplant patients are developed and provided.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of OSE Immunotherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ose Immunotherapeutics
Complete news archive for OSE Immunotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OSE Immunotherapeutics
OSE Immunotherapeutics was founded in 1986 and raised its 1st funding round 31 years after it was founded.
OSE Immunotherapeutics is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.
As of Dec 31, 2024, the latest employee count at OSE Immunotherapeutics is 64.
Annual revenue of OSE Immunotherapeutics is $72.6M as on Dec 31, 2024.
Founded in 1986 in Nantes, France, the company operates in the biotechnology sector, focusing on immunotherapies for immuno-oncology and autoimmune conditions. Key developments include the Tedopi vaccine targeting lung, ovarian, and pancreatic cancers, alongside the CoVepiT vaccine for COVID-19, OSE-172 and CLEC-1 for various cancers, a bispecific fusion protein platform, OSE-127 for ulcerative colitis and Sjogrens syndrome, FR104 for autoimmune diseases and transplantation, and OSE-230 for inflammation.
OSE Immunotherapeutics's top competitors include CareDx, ADMA Biologics and BioNTech.
OSE Immunotherapeutics offers Tedopi, OSE-279, Lusvertikimab, and Pegrizeprument.
Yes, OSE Immunotherapeutics is publicly traded on EURONEXT under the ticker symbol OSE.
OSE Immunotherapeutics has 1 investor. Key investors include Bpifrance.
The ticker symbol of OSE Immunotherapeutics is OSE on EURONEXT.